The aim of the Site Drug project is to develop innovative drug products, which are able to control the resulting drug distribution in the patient’s body: the drug amount at the site of action is to be optimized, and the amount that is “lost” into the rest of the human body is to be minimized. This is to be achieved by “site-specific delivery systems”, which release the drug at a controlled rate at the site of action. Thus, the therapeutic efficacy will be improved and undesired side effects reduced. This will help reducing the current cost burden on our healthcare systems due to adverse drug effects. Specifically, the project aims at developing innovative site-specific drug delivery systems for patients suffering from:
a) Crohn’s disease and ulcerative colitis
b) Ovarian cancer with metastases in the peritoneal cavity
c) Breast resection due to cancer
d) Hearing loss/deafness
This project is funded by the Interreg 2 Seas programme 2014-2020 and the European Regional Development Fund under subsidy contract “Site Drug 2S07-033” (Start Date: 01/01/2020; End Date: 30/09/2022)
More coming soon…